New York, December 13, 2023 - BioStem Technologies (OTC: BSEM) has announced the appointment of Thomas J. Dugan to the position of Chairman of the Board. Mr. Dugan brings a wealth of experience to the role, with proven, hands-on expertise as a senior executive who has extensive experience in the wound care and surgical fields.
BioStem Technologies CEO Jason Matuszewski
I am delighted to welcome Mr. Dugan to BioStem’s Board of Directors. We look forward to benefiting from his extensive leadership and industry experience as we work to optimize value for our shareholders.”
BioStem Technologies CEO Jason Matuszewski
Highlights
Mr. Dugan co-founded 360 Life Sciences Advisors, a consultancy to private equity and venture capital firms, to assess new investment opportunities and improve performance at portfolio companies.
Most recently, Mr. Dugan was the President of Integrum, Inc., the pioneer in osseointegrated orthopedic implants that improve the lives of those with limb loss. Previously, he served as Chief Executive Officer and board member at Amniox Medical, a pioneer in amniotic membrane products for wound care and surgical applications.
Mr. Dugan served on the board of directors of Rita Medical Systems (NASDAQ: RITA), which was acquired by AngioDynamics, and various venture-backed medical device companies. He chaired the Wound Healing and Tissue Regeneration sector of AdvaMed and also served on the board of MITA, the industry trade group for medical imaging.
BioStem Technologies - VENDAJE®
About BioStem Technologies
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB). These systems and procedures are established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC® and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA-registered and AATB-accredited site in Pompano Beach, Florida. For more information, visit biostemtechnologies.com and follow us on Twitter and LinkedIn.